Valuation: Rock Creek Pharmaceuticals Inc

Market Cap 153K 134K 124K 114K 216K 14.79M 219K 1.49M 582K 7.24M 576K 563K 24.93M P/E 2014
-0.87x
P/E 2015 -1.04x
Enterprise Value 20.01M 17.53M 16.21M 14.9M 28.17M 1.93B 28.59M 194M 75.93M 944M 75.14M 73.49M 3.25B EV / Sales 2014
-
EV / Sales 2015 -
Free-Float
100%
Yield 2014 *
-
Yield 2015 -
Change 5-day change 1-year change 3-year change Capi.($)
-16.67%+25.00% - - 17.04K
-2.73%-3.51%+48.62%+152.87% 1,051B
-1.67%-3.18%+52.00%+56.75% 609B
-0.44%+2.14%+33.88%+84.04% 450B
-0.75%-1.46%+28.32%+22.33% 330B
-1.52%-0.95%+33.38%+38.39% 284B
-1.70%-3.54%+20.26%+17.88% 263B
-0.58%+1.78%-20.89%-38.37% 223B
-0.58%+0.21%+23.55%+56.94% 198B
-0.80%+2.60%+23.09%+68.71% 167B
Average -1.92%+0.54%+26.91%+51.06% 397.23B
Weighted average by Cap. +0.35%+0.02%+35.25%+75.58%

Financials

2014 2015
Net sales - -
Net income -38.52M -33.75M -31.21M -28.69M -54.22M -3.71B -55.04M -373M -146M -1.82B -145M -141M -6.26B -6.84M -6M -5.55M -5.1M -9.64M -660M -9.78M -66.3M -25.97M -323M -25.7M -25.14M -1.11B
Net Debt -45K -39.43K -36.46K -33.51K -63.34K -4.34M -64.3K -436K -171K -2.12M -169K -165K -7.31M 19.86M 17.4M 16.09M 14.79M 27.95M 1.91B 28.38M 192M 75.35M 937M 74.56M 72.93M 3.23B
Logo Rock Creek Pharmaceuticals Inc
Rock Creek Pharmaceuticals Inc is a United States-based pharmaceutical development company. The Company is focused on the discovery, development and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its activities are focused on its lead compound, anatabine citrate (anatabine). Anatabine is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics. The Company focuses on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its formulations of anatabine.
Employees
-